×

Product Overview

MyPath-Melanoma-RGB

MyPath Melanoma was validated in cutaneous melanocytic lesions to accurately differentiate between benign and malignant melanocytic lesions of unknown potential, based on the expression of 23 genes using standard quantitative qRT-PCR that provides an accurate and objective classification suggestive of benign, intermediate, or malignant.

MyPath Melanoma has demonstrated reproducible results across 10 publications including validation to dermatopathology experts' diagnoses and outcomes.

DiffDx-Melanoma-RGB

The DecisionDx DiffDx-Melanoma test was validated in cutaneous melanocytic lesions to accurately differentiate between benign and malignant melanocytic lesions of unknown potential based on the expression of 35 genes using standard quantitative qRT-PCR that provides an accurate classification suggestive of benign, intermediate, or malignant.

DiffDx-Melanoma has demonstrated high levels of both sensitivity and specificity with a low rate of intermediate results across a wide range of melanocytic subtypes and high rate of technical success.

melhcp-riskidentified.svg

Order MyPath® Melanoma

For Information

Call: 866-788-9007

Video Webinar

An introduction to our diagnostic GEP by Castle Biosciences Medical Director Matthew Goldberg, MD.

Expert Opinions in Melanoma

When Is the MyPath Melanoma Test Most Helpful

On-Demand
Educational Programs

What's Next?

MyPath Melanoma
Clinical Evidence

How Do You Order a
MyPath Melanoma Test?

Scroll to Top
Scroll to Top